novartis ag-sponsored adr (NVS:New York)
Transactions by NOVARTIS AG-SPONSORED ADR (NVS) in the last 6 months
Aduro BioTech, Inc. announced that it has received $25 million in a round of funding from new investor Novartis AG on March 30, 2015. As a result of the transaction, the investor has acquired 2.7% stake in the company. The investor has also committed to invest another $25 million at a future date,
GlaxoSmithKline plc (LSE:GSK) acquired 4.96% stake in Valneva SE (ENXTPA:VLA) from Novartis AG (SWX:NOVN) on March 3, 2015.
Caribou Biosciences, Inc. announced that it has received $11.55 in its series A round of equity funding from Novartis AG on January 7, 2015. The transaction included participation from Fidelity Biosciences, Mission Bay Capital, 5 Prime Ventures, an undisclosed strategic partner, and Jennifer Doudna, co-founder of the company. As a part of transaction, Robert Weisskoff of Fidelity Biosciences joined the company’s board of directors.
Mission Bay Capital LLC
|Gilead Sciences Inc||$112.27 USD||-0.58|
|Johnson & Johnson||$100.14 USD||-1.01|
|Merck & Co Inc||$60.89 USD||+1.19|
|Pfizer Inc||$34.75 USD||+0.31|
|Roche Holding AG||SFr.276.20 CHF||-6.30|
|View Industry Companies|